the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
NCT ID: NCT07338851
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
600 participants
OBSERVATIONAL
2026-01-30
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR
NCT04638985
Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA
NCT04636827
An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses
NCT04989231
Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP
NCT04053010
Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live
NCT05161845
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
5 years of follow-up group
All the children who met the protocol criteria and had been five years since their last doses of sIPV, MMR or HepA-L were included.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The time window from the day of enrollment to the date when the participants received the fourth dose of sIPV vaccine, the second dose of MMR vaccine, or the first dose of HepA-L vaccine was 60 to 66 months.
* The informed consent form shall be signed by the participant or his/her legal guardian and dated.
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shaanxi Provincial Center for Disease Control and Prevention
OTHER
Hubei Provincial Center for Disease Control and Prevention
OTHER
Jiangsu Provincial Center for Disease Control and Prevention
UNKNOWN
Anhui Provincial Center for Disease Control and Prevention
UNKNOWN
Sichuan Provincial Center for Disease Control and Prevention
UNKNOWN
China National Biotec Group Company Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Si County Center for Disease Control and Prevention
Suzhou, Anhui, China
Feixiang District Center for Disease Control and Prevention
Handan, Hebei, China
Sheyang County Center for Disease Control and Prevention
Yancheng, Jiangsu, China
Chenggu County Center for Disease Control and Prevention
Hanzhong, Shaanxi, China
Yanhu District Center for Disease Control and Prevention
Yuncheng, Shanxi, China
Jiangyou Center for Disease Control and Prevention
Mianyang, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
sIPV/MMR/HepA-L-2025-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.